Finoriq research workspace
Natera, Inc. (NTRA) SEC Filings & Filing Highlights
Natera, Inc., a diagnostics company, engages in the development and commercialization of. Review NTRA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
- Company
- Natera, Inc. (NTRA)
- Ticker
- NTRA
- Market Cap
- $37.8B
- Latest Price
- $263.81
- Industry
- Medical Devices
Natera, Inc. (NTRA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Natera, Inc. (NTRA).
| Event | Form | Date |
|---|---|---|
| On July 1, 2026, Monica Bertagnolli notified the Board of Directors (the “Board”) of Natera, In...On July 1, 2026, Monica Bertagnolli notified the Board of Directors (the “Board”) of Natera, Inc. (“Natera” or the “Company”) of her intent... | 8-K5.02 | 2026-07-06 |
| On June 11, 2026, at the Annual Meeting, the Company’s stockholders voted on five proposals, ea...On June 11, 2026, at the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in t... | 8-K5.07 | 2026-06-16 |
| As described below, on June 11, 2026, Natera, Inc. (the “Company”) held its Annual Meeting of S...As described below, on June 11, 2026, Natera, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the A... | 8-K5.02 | 2026-06-16 |
| The Board of Directors (the “Board”) of Natera, Inc., a Delaware corporation (the “Company”) (i...The Board of Directors (the “Board”) of Natera, Inc., a Delaware corporation (the “Company”) (i) increased the size of the full Board from... | 8-K5.02 | 2026-06-05 |
| Natera Reports First Quarter 2026 Financial ResultsNatera Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-07 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.